BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29301143)

  • 21. The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers.
    Cremers RG; Eeles RA; Bancroft EK; Ringelberg-Borsboom J; Vasen HF; Van Asperen CJ; ; Schalken JA; Verhaegh GW; Kiemeney LA
    Urol Oncol; 2015 May; 33(5):202.e19-28. PubMed ID: 25746941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis.
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    BJU Int; 2008 Jun; 101(12):1507-12. PubMed ID: 18341627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
    Spurgeon SE; Mongoue-Tchokote S; Collins L; Priest R; Hsieh YC; Peters LM; Beer TM; Mori M; Garzotto M
    Urology; 2007 May; 69(5):931-5. PubMed ID: 17482937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    Ibrahim M; Yadav S; Ogunleye F; Zakalik D
    BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.
    Castro E; Goh C; Leongamornlert D; Saunders E; Tymrakiewicz M; Dadaev T; Govindasami K; Guy M; Ellis S; Frost D; Bancroft E; Cole T; Tischkowitz M; Kennedy MJ; Eason J; Brewer C; Evans DG; Davidson R; Eccles D; Porteous ME; Douglas F; Adlard J; Donaldson A; Antoniou AC; Kote-Jarai Z; Easton DF; Olmos D; Eeles R
    Eur Urol; 2015 Aug; 68(2):186-93. PubMed ID: 25454609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
    Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ
    BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis.
    Martin NE; Chen MH; Catalona WJ; Loeb S; Roehl KA; D'Amico AV
    Cancer; 2008 Aug; 113(4):717-22. PubMed ID: 18615505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Wolters T; Roobol MJ; Bangma CH; Schröder FH
    Eur Urol; 2009 Feb; 55(2):385-92. PubMed ID: 18353529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
    Sessine MS; Das S; Park B; Salami SS; Kaffenberger SD; Kasputis A; Solorzano M; Luke M; Vince RA; Kaye DR; Borza T; Stoffel EM; Cobain E; Merajver SD; Jacobs MF; Milliron KJ; Caba L; van Neste L; Mondul AM; Morgan TM
    Urology; 2021 Oct; 156():96-103. PubMed ID: 34280438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.
    Gulati R; Cheng HH; Lange PH; Nelson PS; Etzioni R
    Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):222-227. PubMed ID: 27742670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of prostate-specific antigen velocity in prostate cancer early detection.
    Potter SR; Carter HB
    Curr Urol Rep; 2000 May; 1(1):15-9. PubMed ID: 12084336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen velocity (PSAV) and PSAV per initial volume (PSAVD) for early detection of prostate cancer in Chinese men.
    Zheng XY; Zhang P; Xie LP; You QH; Cai BS; Qin J
    Asian Pac J Cancer Prev; 2012; 13(11):5529-33. PubMed ID: 23317212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations.
    Rajwa P; Quhal F; Pradere B; Gandaglia G; Ploussard G; Leapman MS; Gore JL; Paradysz A; Tilki D; Merseburger AS; Morgan TM; Briganti A; Palapattu GS; Shariat SF
    Nat Rev Urol; 2023 Apr; 20(4):205-216. PubMed ID: 36600087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer.
    Castro E; Mikropoulos C; Bancroft EK; Dadaev T; Goh C; Taylor N; Saunders E; Borley N; Keating D; Page EC; Saya S; Hazell S; Livni N; deSouza N; Neal D; Hamdy FC; Kumar P; Antoniou AC; Kote-Jarai Z; ; Eeles RA
    Oncologist; 2016 Jun; 21(6):716-22. PubMed ID: 27151655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.
    Mahal BA; Aizer AA; Efstathiou JA; Nguyen PL
    Cancer; 2016 Jan; 122(1):78-83. PubMed ID: 26371600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report.
    Hemal S; DeWitt-Foy M; Klein EA
    Urology; 2021 Jul; 153():129-131. PubMed ID: 33556450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of preoperative PSA velocity in men with low serum PSA and normal DRE.
    Makarov DV; Loeb S; Magheli A; Zhao K; Humphreys E; Gonzalgo ML; Partin AW; Han M
    World J Urol; 2011 Feb; 29(1):11-4. PubMed ID: 21153643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does PSA velocity predict prostate cancer in pre-screened populations?
    Schröder FH; Roobol MJ; van der Kwast TH; Kranse R; Bangma CH
    Eur Urol; 2006 Mar; 49(3):460-5; discussion 465. PubMed ID: 16442212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
    Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
    Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.